Llwytho...
Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
Background: Denosumab is a RANK-l inhibitor that, in addition to the treatment of osteoporosis, is used in patients with advanced cancer and metastatic bone disease to prevent skeletal-related events. Although denosumab is generally safe and effective, it can cause hypocalcemia which in some patient...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Endocr Soc |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089690/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.385 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|